JP2001220352A - Cathartic medicine - Google Patents
Cathartic medicineInfo
- Publication number
- JP2001220352A JP2001220352A JP2000029948A JP2000029948A JP2001220352A JP 2001220352 A JP2001220352 A JP 2001220352A JP 2000029948 A JP2000029948 A JP 2000029948A JP 2000029948 A JP2000029948 A JP 2000029948A JP 2001220352 A JP2001220352 A JP 2001220352A
- Authority
- JP
- Japan
- Prior art keywords
- water
- powder
- soluble polymer
- seed coat
- plantago
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 27
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 15
- 241001127637 Plantago Species 0.000 claims description 24
- -1 silicate compound Chemical class 0.000 claims description 14
- 239000008141 laxative Substances 0.000 claims description 12
- 230000002475 laxative effect Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 235000012239 silicon dioxide Nutrition 0.000 abstract description 9
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 abstract description 5
- 244000134552 Plantago ovata Species 0.000 abstract 2
- 235000003421 Plantago ovata Nutrition 0.000 abstract 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 241001499741 Plantago arenaria Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 235000010451 Plantago psyllium Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100031083 Uteroglobin Human genes 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、良好な水分散性を
有し、服用性に優れたプランタゴオバタ種皮末含有瀉下
薬に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a cathartic drug containing plantago obata seed coat powder which has good water dispersibility and is easy to take.
【０００２】[0002]
【従来の技術】プランタゴオバタはインド産のオオバコ
科に属する植物で、その種皮は膨潤性瀉下薬の成分とし
て知られ、医薬品分野において広く利用されている。従
来のプランタゴオバタ製剤は、顆粒状に製されたものを
水で服用することが多かった。しかしながら、プランタ
ゴオバタ種皮は水に接触すると膨潤し、体積を約５０倍
増加する性質を有し、服用後に膨潤し、消化管内で滞留
してしまうおそれがあった。そのためプランタゴオバタ
種皮を服用する際には、あらかじめ水に膨潤させておく
ことが好ましいが、プランタゴオバタ種皮は膨潤性と共
に強い凝集性を呈する性質ももつため、ダマを生じ、均
一に分散させることは困難であった。プランタゴオバタ
種皮の水分散性を改善する試みは、糖類を添加すること
による表面改質（特公平4-30925）、油脂中に分散させ
る方法（特公平6-72106）などが知られているが、分散
性が充分でないため、服用しづらく、さらなる改善が望
まれている。2. Description of the Related Art Plantago obata is a plant belonging to the plantain family of India, and its seed coat is known as a component of swellable laxatives and is widely used in the pharmaceutical field. Conventional plantago obata preparations are often taken in water in the form of granules. However, plantago obata seed coat swells when it comes in contact with water, has the property of increasing its volume by about 50 times, swells after taking it, and may remain in the digestive tract. Therefore, when taking the plantago obata seed coat, it is preferable to swell it in water in advance, but since the plantago obata seed coat also has the property of exhibiting strong cohesiveness as well as swelling, it is not possible to generate lumps and disperse uniformly It was difficult. Attempts to improve the water dispersibility of plantago obata seed coat include surface modification by adding saccharides (Japanese Patent Publication No. 4-30925) and a method of dispersing in oils and fats (Japanese Patent Publication No. 6-72106). Since the dispersibility is not sufficient, it is difficult to take the drug, and further improvement is desired.
【０００３】[0003]
【発明が解決しようとする課題】本発明の目的は、良好
な水分散性を有し、服用性に優れたプランタゴオバタ種
皮末含有瀉下薬を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a plantago obata seed powder-containing laxative having good water dispersibility and excellent ingestibility.
【０００４】[0004]
【課題を解決するための手段】上記課題を解決するため
に、本発明者らは鋭意研究を重ねた結果、プランタゴオ
バタ種皮末に水溶性高分子及びケイ酸化合物を添加する
ことにより、更にはそれらの添加量を極めて狭い特定量
とすることにより水分散性がよく、服用性の優れたプラ
ンタゴオバタ瀉下薬が得られることを見い出し、本発明
を完成した。すなわち本発明は、プランタゴオバタ種皮
末、水溶性高分子及びケイ酸化合物を含有する瀉下薬で
ある。Means for Solving the Problems In order to solve the above-mentioned problems, the present inventors have made intensive studies and as a result, by adding a water-soluble polymer and a silicate compound to plantago obata seed coat powder, furthermore, It has been found that by setting the addition amount to a very narrow specific amount, a plantago obata laxative excellent in water dispersibility and excellent in ingestibility can be obtained, and the present invention has been completed. That is, the present invention is a cathartic containing plantago obata seed coat powder, a water-soluble polymer and a silicate compound.
【０００５】[0005]
【発明の実施の形態】本発明において、水溶性高分子と
は、結合剤として通常用いられるものをいい、ヒドロキ
シプロピルセルロース、ポリビニルピロリドン、ヒドロ
キシプロピルメチルセルロース等を挙げることができ
る。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, a water-soluble polymer refers to a polymer usually used as a binder, and examples thereof include hydroxypropylcellulose, polyvinylpyrrolidone, and hydroxypropylmethylcellulose.
【０００６】本発明において、ケイ酸化合物とは、軽質
無水ケイ酸、メタケイ酸アルミン酸マグネシウム、ケイ
酸アルミン酸マグネシウム、ケイ酸カルシウム、ケイ酸
マグネシウム、ケイ酸アルミニウム等を挙げることがで
き、好ましくは軽質無水ケイ酸、メタケイ酸アルミン酸
マグネシウムである。In the present invention, examples of the silicate compound include light silicic anhydride, magnesium metasilicate aluminate, magnesium silicate aluminate, calcium silicate, magnesium silicate, aluminum silicate and the like. Light anhydrous silicic acid and magnesium aluminate metasilicate.
【０００７】本発明において、水溶性高分子及びケイ酸
化合物の含有量は、プランタゴオバタ種皮末１質量部に
対し水溶性高分子を０．０１〜０．０９質量部、ケイ酸
化合物を０．００１〜０．０５質量部含有するのがよ
く、より好ましくは水溶性高分子が０．０５〜０．０８
質量部、ケイ酸化合物が０．００５〜０．０１５であ
る。In the present invention, the content of the water-soluble polymer and the silicic acid compound is 0.01 to 0.09 parts by mass of the water-soluble polymer and 0.1 wt. 001 to 0.05 parts by mass, more preferably 0.05 to 0.08 water-soluble polymer.
Parts by mass and the silicate compound are 0.005 to 0.015.
【０００８】本発明の瀉下薬は、通常、以下に例示する
ように、湿式造粒法を用いて製造される。 プランタゴオバタ種皮末にケイ酸化合物を加えて混合
し、これに水溶性高分子の結合液を噴霧し、乾燥して製
する。 プランタゴオバタ種皮末にケイ酸化合物及び水溶性高
分子を加えて混合し、これに水溶性高分子の結合液を噴
霧し、乾燥して製する。 プランタゴオバタ種皮末に、ケイ酸化合物を均一に分
散させた水溶性高分子の結合液を噴霧し、乾燥して製す
る。 プランタゴオバタ種皮末にケイ酸化合物及び／又は水
溶性高分子を加えて混合し、これにケイ酸化合物を均一
に分散させた水溶性高分子の結合液を噴霧し、乾燥して
製する。なお、結合液の溶媒としては、水、アルコー
ル、含水アルコールを挙げることができ、適宜、選択し
て使用することができる。[0008] The laxative of the present invention is usually produced by a wet granulation method as exemplified below. A silicic acid compound is added to and mixed with the plantago obata seed coat powder, and a binding solution of a water-soluble polymer is sprayed onto the powder, followed by drying to produce a product. A silicic acid compound and a water-soluble polymer are added to and mixed with the plantago psyllium seed coat powder, and a binding solution of the water-soluble polymer is sprayed onto the powder and dried to produce a product. A binding solution of a water-soluble polymer in which a silicic acid compound is uniformly dispersed is sprayed onto a plantago obata seed coat powder, and dried to produce a powder. A silicate compound and / or a water-soluble polymer is added to and mixed with the plantago obata seed coat powder, and a water-soluble polymer binding solution in which the silicate compound is uniformly dispersed is sprayed and dried to produce the product. In addition, as a solvent of the binding liquid, water, alcohol, and hydrous alcohol can be exemplified, and can be appropriately selected and used.
【０００９】装置としては、流動層造粒機、高速攪拌型
造粒機、転動流動層造粒機等を用いることができる。As the apparatus, a fluidized bed granulator, a high speed stirring type granulator, a tumbling fluidized bed granulator and the like can be used.
【００１０】また、本発明の効果を損なわない範囲で、
通常の医薬品製造に使用される添加剤を加え、常法によ
り、例えば散剤、顆粒剤、ドライシロップ剤等の剤形と
することができる。[0010] In addition, as long as the effects of the present invention are not impaired,
Additives commonly used in the production of pharmaceuticals are added, and the preparation can be made into a dosage form such as a powder, a granule, a dry syrup or the like by a conventional method.
【００１１】上記のようにして得られたプランタゴオバ
タ種皮末含有瀉下薬は、良好な水分散性を有し、服用性
も優れたものである。また、服用後、消化管内におい
て、滞留してしまうおそれもない。The laxative containing plantago obata seed powder obtained as described above has good water dispersibility and is excellent in ingestibility. In addition, there is no danger of staying in the digestive tract after taking.
【００１２】[0012]
【発明の効果】本発明により、良好な水分散性を有し、
服用性に優れたプランタゴオバタ種皮末含有瀉下薬を提
供することが可能となった。According to the present invention, it has good water dispersibility,
It has become possible to provide a laxative containing plantago obata seed coat powder that is excellent in ingestibility.
【００１３】[0013]
【実施例】以下に試験例及び実施例をあげて本発明を更
に詳細に説明する。The present invention will be described in more detail with reference to the following Test Examples and Examples.
【００１４】実施例１ プランタゴオバタ種皮末３１０．５ｇ、ヒドロキシプロ
ピルセルロース１７．３ｇ、軽質無水ケイ酸３．３ｇを
秤り、混合後、粉砕機を用いて粉砕し、得られた混合粉
砕物を流動層造粒機を用いて、７質量％ヒドロキシプロ
ピルセルロース水溶液をヒドロキシプロピルセルロ―ス
の噴霧量が４．９ｇになるまで噴霧し、造粒した。乾燥
後、篩過することにより整粒し、これにブドウ糖３４
７．０ｇ、マンニトール１９．０ｇ、アスパルテーム
２．７ｇ、無水クエン酸１５．３ｇを加えて、混合し散
剤を得た。Example 1 310.5 g of plantago obata seed coat powder, 17.3 g of hydroxypropylcellulose, and 3.3 g of light anhydrous silicic acid were weighed, mixed, and then pulverized using a pulverizer. Using a fluidized bed granulator, a 7% by mass aqueous solution of hydroxypropylcellulose was sprayed and granulated until the spray amount of hydroxypropylcellulose became 4.9 g. After drying, the mixture is sieved and sized to give glucose 34.
7.0 g, mannitol 19.0 g, aspartame 2.7 g, and citric anhydride 15.3 g were added and mixed to obtain a powder.
【００１５】実施例２ プランタゴオバタ種皮末３１０．５ｇ、ヒドロキシプロ
ピルセルロース１７．３ｇ、メタケイ酸アルミン酸マグ
ネシウム２．７ｇを秤り、混合後、粉砕機を用いて粉砕
し、得られた混合粉砕物を流動層造粒機を用いて、７質
量％ヒドロキシプロピルセルロース水溶液中にメタケイ
酸アルミン酸マグネシウムを０．８６質量％になるよう
に均一に分散させた結合液で噴霧量がメタケイ酸アルミ
ン酸マグネシウム０．６ｇ、ヒドロキシプロピルセルロ
―ス４．９ｇになるまで噴霧し、造粒した。乾燥後、篩
過することにより整粒し、これに粉末還元麦芽糖水飴３
４７．０ｇ、マンニトール１９．０ｇ、アスパルテーム
２．７ｇ、無水クエン酸１５．３ｇを加えて、混合し散
剤を得た。Example 2 310.5 g of plantago obata seed powder, 17.3 g of hydroxypropylcellulose, and 2.7 g of magnesium aluminate metasilicate were weighed, mixed, and then pulverized using a pulverizer. Using a fluidized bed granulator, a spray amount of magnesium aluminate metasilicate was uniformly dispersed in a 7% by mass aqueous solution of hydroxypropylcellulose using a binder liquid in which magnesium aluminate metasilicate was uniformly dispersed to 0.86% by mass. Spraying was performed until 0.6 g and 4.9 g of hydroxypropyl cellulose were obtained, and the mixture was granulated. After drying, the mixture is sieved and sized to obtain a powdered reduced maltose syrup 3
47.0 g, mannitol 19.0 g, aspartame 2.7 g, and citric anhydride 15.3 g were added and mixed to obtain a powder.
【００１６】比較例１ 実施例１において、軽質無水ケイ酸を抜き、マンニトー
ルを２２．３ｇとし、他の成分は同じ質量としたものに
つき、実施例１に準拠し、散剤とした。Comparative Example 1 In Example 1, light anhydrous silicic acid was removed, mannitol was used in an amount of 22.3 g, and other components having the same mass were used as a powder in accordance with Example 1.
【００１７】比較例２ 実施例１において、軽質無水ケイ酸を２０．０ｇ、ブド
ウ糖を３３０．３ｇとし、他の成分は同じ質量としたも
のにつき、実施例１に準拠し、散剤とした。Comparative Example 2 In Example 1, 20.0 g of light anhydrous silicic acid, 330.3 g of glucose, and other components having the same mass were used as powders according to Example 1.
【００１８】試験例 実施例及び比較例で得られたプランタゴオバタ種皮末含
有瀉下薬について、下記の試験を行った。Test Examples The following tests were carried out on the laxatives containing plantago obata seed powder obtained in Examples and Comparative Examples.
【００１９】試験例１ 水分散性の評価 試験方法 実施例１、２及び比較例１で得たプランタゴオバタ種皮
末含有瀉下薬８．０ｇを、１５０ｍＬの精製水を入れ、
攪拌子で回転させたガラスビーカー中に投入し、そのと
きの水分散性を目視により、評価した。結果を表１に示
した。表１から明らかなように、実施例１、２は比較例
１より水分散性が良好であった。Test Example 1 Evaluation of water dispersibility Test method 150 g of purified water containing 8.0 g of the laxative containing plantago obata seed powder obtained in Examples 1 and 2 and Comparative Example 1 was added thereto.
It was put into a glass beaker rotated with a stirrer, and the water dispersibility at that time was visually evaluated. The results are shown in Table 1. As is clear from Table 1, Examples 1 and 2 had better water dispersibility than Comparative Example 1.
【００２０】[0020]
【表１】 水分散性試験結果 試験例２ 服用性の評価 試験方法 実施例１、２及び比較例１、２で得たプランタゴオバタ
種皮末含有瀉下薬８．０ｇを、１５０ｍＬの精製水に分
散させたものにつき服用性を評価した。結果は表２に示
すように、実施例１、２は、比較例１、２に比較して口
中において滑らかな触感があり、優れた服用性を示し
た。[Table 1] Water dispersibility test results Test Example 2 Evaluation of ingestibility Test method Evaluating the ingestibility of 8.0 g of the plantago obata seed skin powder-containing laxative obtained in Examples 1 and 2 and Comparative Examples 1 and 2 dispersed in 150 mL of purified water. . As shown in Table 2, the results of Examples 1 and 2 were smoother in the mouth than in Comparative Examples 1 and 2, and showed excellent ingestibility.
【００２１】[0021]
【表２】 服用性試験結果 [Table 2] Results of ingestion test
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ｃ０８Ｋ 3/34 Ｃ０８Ｋ 3/34 Ｃ０８Ｌ 99/00 Ｃ０８Ｌ 99/00 101/14 101/14 (72)発明者 恒成 嘉伸 東京都豊島区高田３丁目24番地１号 大正 製薬株式会社内 Ｆターム(参考） 4C076 AA30 BB01 CC16 DD27 DD29 EE16A EE32A FF05 FF43 GG12 4C088 AB22 AC04 MA41 MA52 NA03 NA20 ZA72 4J002 AB012 AJ001 BJ002 DJ006 DJ016 FD206 GB04 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) C08K 3/34 C08K 3/34 C08L 99/00 C08L 99/00 101/14 101/14 (72) Inventor Yoshinobu Tsuneari 3-24-1, Takada, Toshima-ku, Tokyo F-term (reference) 4C076 AA30 BB01 CC16 DD27 DD29 EE16A EE32A FF05 FF43 GG12 4C088 AB22 AC04 MA41 MA52 NA03 NA20 ZA72 4J002 AB012 AJ001 016006 DJ GB04
Claims (3)
びケイ酸化合物を含有する瀉下薬。1. A laxative containing plantago obata seed coat powder, a water-soluble polymer and a silicate compound.
水溶性高分子を０．０１〜０．０９質量部、及びケイ酸
化合物を０．００１〜０．０５質量部含有する請求項１
に記載の瀉下薬。2. An amount of 1 part by mass of plantago obata seed coat powder
The water-soluble polymer is contained in an amount of 0.01 to 0.09 parts by mass and a silicate compound in an amount of 0.001 to 0.05 parts by mass.
The laxative described in the above.
２に記載の瀉下薬。3. The laxative according to claim 1, which is produced by a wet granulation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000029948A JP2001220352A (en) | 2000-02-08 | 2000-02-08 | Cathartic medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000029948A JP2001220352A (en) | 2000-02-08 | 2000-02-08 | Cathartic medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001220352A true JP2001220352A (en) | 2001-08-14 |
Family
ID=18555027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000029948A Pending JP2001220352A (en) | 2000-02-08 | 2000-02-08 | Cathartic medicine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001220352A (en) |
-
2000
- 2000-02-08 JP JP2000029948A patent/JP2001220352A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3138525A (en) | Castor wax-amprotropine-resin compositions | |
| JP3667778B2 (en) | Spheroid preparation | |
| US4254099A (en) | Pharmaceutical tablet composition | |
| WO1997031639A1 (en) | TABLETS CONTAINING β-LACTAM ANTIBIOTIC AND PROCESS FOR PRODUCING THE SAME | |
| JP2006124695A (en) | Granular composition of anion exchange resin and method for producing the same | |
| AT413647B (en) | USE OF A COPOLYMERISATE OF 1-VINYL-2-PYRROLIDONE AND VINYL ACETATE FOR THE PREPARATION OF CEFUROXIMAXETIL-SUBJECTED TABLETS | |
| WO1997013516A1 (en) | Antibacterial composition for oral administration | |
| CA2055905C (en) | Pharmaceutical composition comprising calcium polycarbophil | |
| JPH0717866A (en) | Medicinal composition | |
| JPH10203985A (en) | Production of taste-masking agent of antibacterial quinolone derivative | |
| JP3319625B2 (en) | Fast-disintegrating crude drug formulation | |
| JPH05320045A (en) | Spray drying method for manufacturing medicine powder composition being compressable directly to tablet | |
| JP2004529178A (en) | Taste masking pharmaceutical composition | |
| JPS63150220A (en) | Preparation of solid drug for oral administration | |
| JPS63104925A (en) | Solid bile acid agent | |
| JPS6320409B2 (en) | ||
| JP2001220352A (en) | Cathartic medicine | |
| JPS6137247B2 (en) | ||
| CN110314150A (en) | A kind of Telmisartan flavor chewable tablets and preparation method thereof | |
| JPS5959632A (en) | Sustained release composition | |
| JP2506812B2 (en) | Vitamin E-containing powder with good water dispersibility | |
| JP3796848B2 (en) | Herbal medicine-containing solid composition | |
| JPH09100229A (en) | Solid preparation containing loxoprofen sodium | |
| JP2004277431A (en) | Granular preparation and method of producing the same | |
| JP4475693B2 (en) | Acetaminophen-containing foam composition |